Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

FDA accepts Amgen's evolocumab BLA for review

Amgen today announced that the U.S. Food and Drug Administration has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol.

11 Nov 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.

11 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

New vaccination approach can reduce tumor burden, suppress formation of lung metastases

In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumor vessels can reduce tumor burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer.

9 Nov 2014

Quadrupole time-of-flight mass spectrometry for life science research analysis announced by Bruker

Bruker Corporation (NASDAQ: BRKR) announced today, the evolution of their maXis™ line of ultrahigh-resolution quadrupole time-of-flight (UHR-qTOF) mass spectrometers, bringing industry-leading resolution and mass accuracy to the liquid chromatography, time-of-flight MS market space.

From Bruker 6 Nov 2014

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation.

6 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

In support of a bold quest to rid the world entirely of malaria, the Bill & Melinda Gates Foundation today announced an award of US$156 million to PATH to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the "accelerating to zero" agenda. Such vaccines would ensure that parasite reintroduction is prevented by providing what could be called an "immunological bed net."

3 Nov 2014

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40).

23 Oct 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.

20 Oct 2014

Amgen files lawsuit against Regeneron, Sanofi to prevent infringing manufacture of alirocumab

Amgen today announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Sanofi, Aventisub LLC, formerly doing business as Aventis Pharmaceuticals Inc. (collectively "Sanofi"), and Regeneron Pharmaceuticals, Inc. ("Regeneron") for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741.

17 Oct 2014

Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

The dirt in your backyard may hold the key to isolating cancerous tumors and to potential new treatments for a host of cancers.

14 Oct 2014

Maker of experimental Ebola drug scales up

The manufacturer of the experimental Ebola drug ZMapp says it has put other business on hold since August to boost production of the medication. Meanwhile, news outlets look at the government's authority to screen airline travelers, the House action to release additional funding for disease-fighting efforts and the Dallas hospital's defense of its treatment of the West African man who died of the disease this week.

12 Oct 2014

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

6 Oct 2014

BIDMC receives $20 million grant to evaluate, test monoclonal antibodies for HIV treatment

Beth Israel Deaconess Medical Center has received a four-year, $20 million grant from the Bill & Melinda Gates Foundation to evaluate and test broadly neutralizing monoclonal antibodies for the treatment of HIV.

3 Oct 2014

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

NKT Therapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NKTT120, the company's lead therapeutic being developed for the treatment of sickle cell disease.

3 Oct 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

U-M researchers describe new approach to discovering potential cancer treatments

Researchers at the University of Michigan have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods.

30 Sep 2014

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.

30 Sep 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Monoclonal Antibody News and Research

Further Reading

FDA accepts Amgen's evolocumab BLA for review

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

New vaccination approach can reduce tumor burden, suppress formation of lung metastases

Quadrupole time-of-flight mass spectrometry for life science research analysis announced by Bruker

Biosimilar medications could cut spending on biologics in the U.S. by $44 billion

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Amgen files lawsuit against Regeneron, Sanofi to prevent infringing manufacture of alirocumab

Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

Maker of experimental Ebola drug scales up

Bristol-Myers Squibb, MD Anderson partner to evaluate multiple immunotherapies

BIDMC receives $20 million grant to evaluate, test monoclonal antibodies for HIV treatment

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

U-M researchers describe new approach to discovering potential cancer treatments

Pertuzumab combined with trastuzumab and chemotherapy extends lives of HER2-positive breast cancer patients

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®